Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 112Gynecologic 5Breast 5Thoracic 3Genitourinary 3CNS 3Sarcoma 2Head & Neck 2Dermatologic 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Brain Neoplasms 7Central Nervous System Neoplasms 6Breast Neoplasms 6Pancreatic Neoplasms 5Glioblastoma 5Ovarian Neoplasms 4Neoplasms 4Medulloblastoma 4Glioma 4Sarcoma 3Prostatic Neoplasms 3Osteosarcoma 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Neuroectodermal Tumors, Primitive 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Neoplasm Metastasis 2Multiple Myeloma 2Microphthalmia, Isolated, with Coloboma 5 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Esthesioneuroblastoma, Olfactory 2Diffuse Intrinsic Pontine Glioma 2

Interventions

Magnetic Resonance Spectroscopy 4Nivolumab 3Gemcitabine 3Fluorodeoxyglucose F18 3olutasidenib 2olaparib 2durvalumab 2Specimen Handling 2FAPI-46 2Cisplatin 2ulixertinib 1pembrolizumab 1ivosidenib 1entrectinib 1enasidenib 1cobimetinib 1alectinib 1Topotecan 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Metformin 1Ipilimumab 1Immunotherapy 1Folfox protocol 1Fluoresceins 1Fluorescein 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Gemcitabine × CNS × Clear all
NCT06840886 2026-05-14

A Study of PHST001 in Advanced Solid Tumors

Pheast Therapeutics

Phase 1 Recruiting
272 enrolled
CNSGastrointestinalGynecologic

Ovarian Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡